Dr. Ajay Prakash Abad, MD

Dr. Abad practices at Roswell Park Cancer Institute in Los Angeles, California.

Dr. Abad's NPI, 1639311244, was assigned on March 27, 2009. Dr. Abad graduated from Jacobs School of Medicine and Biomedical Sciences in 2009. Dr. Abad holds New York license 271072.

Dr. Abad's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Dr. Abad's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Dr. Abad is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Abad practices. Vendor and product names are available with a free account.

Neurology is Dr. Abad's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Abad is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Abad is licensed in New York.

Dmand AI lists acute mini-stroke (TIA), cerebrovascular disease, epilepsy, essential tremor, lower back pain, muscle weakness and neuropathy among the conditions Dr. Abad treats.

CMS data shows 109 Medicare services from Dr. Abad across 4 procedure codes in 2024, for 75 Medicare patients. Medicare paid $11,690 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 75 Medicare patients who saw Dr. Abad in 2024. The largest group is 65 to 74, with 31 patients. 71% of them have high blood pressure, and 60% have high cholesterol. 35% are also on Medicaid. Their average risk score is 2.41, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Abad's median patient age at 63, with 55% women.

In 2024, Dr. Abad wrote 848 Medicare Part D claims for 105 patients. 96% of them were for generic drugs. CMS names the drug for 686 of them, across 21 drugs with 11 or more claims each, at $92,579 in total drug cost. In 2023, CMS named 601 claims across 22 drugs.

Dr. Abad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Abad as offering telehealth.

Dmand AI links 9 papers to Dr. Abad, published from 2021 to 2024. 2024 was the busiest year, with 3. The most frequent topics are Brain Neoplasms, Antineoplastic Agents, Alkylating and Glioblastoma. Dr. Abad has published most often in J Neurooncol. Dr. Abad's most frequent co-authors are Robert A. Fenstermaker, MD, Andrew Joseph Fabiano, MD and Nicholas A. Butowski, MD.

Dmand AI links Dr. Abad to 4 clinical trials, 3 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Glioblastoma, Astrocytoma and Gliosarcoma. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 7 general payments to Dr. Abad from 2 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Novocure Inc. paid the most, $541.

Dr. Abad graduated from Jacobs School of Medicine and Biomedical Sciences in 2009.

Dr. Abad is in network with 9 carriers, including Aetna, MVP Health Care and Blue Cross Blue Shield of Massachusetts. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.